Please assess the completion status of the following clinical trial:

Trial Title: Intraluminal Therapy for Helicobacter Pylori Infection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients aged greater than 20 years and less than 75 years~2. Patients have H. pylori infection without prior eradication therapy~3. Patients are willing to receive the intraluminal therapy. The written informed consents will be obtained from all patients prior to enrollment.~Exclusion Criteria:~1. Children and teenagers aged less than 20 years, and adult greater than 75 years~2. Contraindication for endoscopic examination or food retention in the gastric lumen.~3. History of gastrectomy; Gastroduodenal stenosis、deformity or obstruction; Gastroduodenal malignancy, including adenocarcinoma and lymphoma~4. Contraindication to treatment drugs: previous allergic reaction to antibiotics (amoxicillin, clarithromycin, metronidazole), Proton pump inhibitors (lansoprazole), Acetylcystein and Sucralfate; pregnant or lactating women~5. Severe concurrent acute or chronic illness: renal failure, cirrhosis of liver, incurable malignant disease~6. Patients who cannot give informed consent by himself or herself.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Group A (Drug: 7-day triple therapy) (Type: ACTIVE_COMPARATOR): Intervention : Drug: 7-day triple therapy. Patients fail to achieve intraluminal eradication of H. pylori will be randomly assigned to the oral antibiotics rescue therapies with standard 7-day triple therapy ( lansoprazole 30 mg b.i.d., amoxicillin 1 g b.i.d. and clarithromycin 500 mg b.i.d. for 7 days)
- Group B (Drug: 14-day triple therapy) (Type: SHAM_COMPARATOR): Intervention : Drug: 14-day triple therapy. Patients fail to achieve intraluminal eradication of H. pylori will be randomly assigned to the oral antibiotics rescue therapies with standard 14-day triple therapy ( lansoprazole 30 mg b.i.d., amoxicillin 1 g b.i.d. and clarithromycin 500 mg b.i.d. for 14 days).

Based on this trial design, predict the completion outcome and termination type (if applicable).